Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.47 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14521048 | 0.87 | EIF2AK2 (0.68) | AHRMAOBEIF2AK2PDE3BPDE3A | |
| SCHEMBL25899778 | 0.84 | MAOB (0.55) | AHRMAOBEIF2AK2GRIA1CACNG8 | |
| SCHEMBL6980695 | 0.83 | GAA (0.48) | AHRMAOBEIF2AK2GRIA1CACNG8 | |
| SCHEMBL28346887 | 0.83 | GAA (0.52) | AHRMAOBEIF2AK2GRIA1CACNG8 | |
| SCHEMBL20214 | 0.81 | PDE3B (0.66) | AHRMAOBEIF2AK2GRIA1CACNG8 | |
| SCHEMBL31040124 | 0.81 | PDE3B (0.66) | AHRMAOBEIF2AK2GRIA1CACNG8 | |
| SCHEMBL14124533 | 0.81 | TLK2 (0.38) | MAOBGRIA1PDE3BPDE3ASRC | |
| SCHEMBL6981292 | 0.81 | AHR (0.51) | AHRMAOBEIF2AK2GRIA1CACNG8 | |
| SCHEMBL31414247 | 0.79 | MEN1 (0.40) | AHRMAOBPDE3BPDE3AGAA | |
| SCHEMBL27691373 | 0.79 | MAOB (0.50) | AHRMAOBEIF2AK2GRIA1CACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2012178015-A2 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012178015-A2 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-4622336-A | ANALGESICS | SANDOZ LTD. (CH) | 1986-11-11 | — | — | US | disclosed |
| WO-1983002610-A1 | DERIVATIVES OF 3,3-DIALKYL-INDOLIN AND OF 3,3-ALKYLENE-INDOLIN, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | SANDOZ AG (CH) | 1983-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | AHR 4284/4885MAOB 1759/4885EIF2AK2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.